We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Bristol-Myers Squibb (BMY - Free Report) closed at $53.52 in the latest trading session, marking a +0.07% move from the prior day. The stock outpaced the S&P 500's daily loss of 1.82%. At the same time, the Dow lost 2.21%, and the tech-heavy Nasdaq lost 1.7%.
Prior to today's trading, shares of the biopharmaceutical company had gained 5.11% over the past month. This has outpaced the Medical sector's loss of 1.44% and the S&P 500's loss of 2.57% in that time.
Investors will be hoping for strength from BMY as it approaches its next earnings release, which is expected to be February 4, 2019. The company is expected to report EPS of $0.84, up 23.53% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $5.99 billion, up 9.85% from the prior-year quarter.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $3.84 per share and revenue of $22.58 billion. These results would represent year-over-year changes of +27.57% and +8.68%, respectively.
Investors should also note any recent changes to analyst estimates for BMY. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 6.37% higher within the past month. BMY is currently sporting a Zacks Rank of #1 (Strong Buy).
Looking at its valuation, BMY is holding a Forward P/E ratio of 13.92. For comparison, its industry has an average Forward P/E of 17.07, which means BMY is trading at a discount to the group.
We can also see that BMY currently has a PEG ratio of 1.5. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.09 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 86, putting it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
Bristol-Myers Squibb (BMY - Free Report) closed at $53.52 in the latest trading session, marking a +0.07% move from the prior day. The stock outpaced the S&P 500's daily loss of 1.82%. At the same time, the Dow lost 2.21%, and the tech-heavy Nasdaq lost 1.7%.
Prior to today's trading, shares of the biopharmaceutical company had gained 5.11% over the past month. This has outpaced the Medical sector's loss of 1.44% and the S&P 500's loss of 2.57% in that time.
Investors will be hoping for strength from BMY as it approaches its next earnings release, which is expected to be February 4, 2019. The company is expected to report EPS of $0.84, up 23.53% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $5.99 billion, up 9.85% from the prior-year quarter.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $3.84 per share and revenue of $22.58 billion. These results would represent year-over-year changes of +27.57% and +8.68%, respectively.
Investors should also note any recent changes to analyst estimates for BMY. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 6.37% higher within the past month. BMY is currently sporting a Zacks Rank of #1 (Strong Buy).
Looking at its valuation, BMY is holding a Forward P/E ratio of 13.92. For comparison, its industry has an average Forward P/E of 17.07, which means BMY is trading at a discount to the group.
We can also see that BMY currently has a PEG ratio of 1.5. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.09 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 86, putting it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.